Medical Condition News

RSS

AET-GPB educate Americans on the risks of childhood obesity

Aetna and Georgia Public Broadcasting (GPB) have kicked off a 12-month statewide multi-media campaign to raise awareness of the increased risks of childhood obesity.

28 Sep 2009

Combined immunodeficiency results in severe health problems

Researchers at the National Institutes of Health have identified a genetic mutation that accounts for a perplexing condition found in people with an inherited immunodeficiency. The disorder, called combined immunodeficiency, is characterized by a constellation of severe health problems, including persistent bacterial and viral skin infections, severe eczema, acute allergies and asthma, and cancer.

28 Sep 2009

Study links diabetes to atrial fibrillation in women

Diabetes increases by 26 percent the likelihood that women will develop atrial fibrillation (AF), a potentially dangerous irregular heart rhythm that can lead to stroke, heart failure, and chronic fatigue. These are the findings of a new Kaiser Permanente study, published in the October issue of Diabetes Care, a journal of the American Diabetes Association.

28 Sep 2009

Misregulation of SPAK protein may contribute to B-cell lymphoma development

A group led by Dr. Michael Teitell at UCLA has demonstrated that misregulation of the protein SPAK may contribute to B-cell lymphoma development. Their report can be found in the October 2009 issue of the American Journal of Pathology.

28 Sep 2009

Phase 2 clinical trial results of IMO-2055 announced

Idera Pharmaceuticals, Inc., today announced the presentation of final data from a clinical trial evaluating IMO-2055, an agonist of Toll-like Receptor (TLR) 9, as monotherapy in patients with Renal Cell Carcinoma (RCC). The data are being presented during the Eighth International Kidney Cancer Symposium being held in Chicago, September 25-26, 2009.

28 Sep 2009

FDA grants accelerated approval for Allos Therapeutics’ FOLOTYN

Allos Therapeutics, Inc. (Nasdaq:ALTH) today announced that last night the U.S. Food and Drug Administration (FDA) granted accelerated approval for FOLOTYNTM (pralatrexate injection) for use as a single agent for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).

28 Sep 2009

NSERC awards $5M grant to develop faster detection methods for cancer

A nanomedicine research group led by a University of Toronto chemist has received a $5-million grant from the Natural Sciences and Engineering Research Council of Canada (NSERC), giving them the green light to develop faster ways of detecting leukemia and lung cancer cells.

28 Sep 2009

Health inequalities linked to socioeconomic status

Prostate cancer patients of low socioeconomic status are more likely to die than patients with higher incomes. That is the finding of a new study from Swiss researchers to be published in the December 1, 2009 issue of CANCER, a peer-reviewed journal of the American Cancer Society.

28 Sep 2009

Improving the accuracy of violent behaviour prediction may alleviate negative effects of violence

In the future, diagnosing severe personality disorders, evaluating the childhood environment, assessing alcohol consumption and the analysis of the MAOA genotype may provide more accurate means for assessing risk among violent offenders, according to the Finnish research carried out jointly at the University of Helsinki and the Helsinki University Central Hospital Psychiatry Centre.

28 Sep 2009

Podiatric experts recommend team approach for diabetic foot care

Every 30 seconds, across the globe an individual loses a limb due to poor diabetes management. In the U.S., diabetes affects nearly 24 million people. When poorly controlled, diabetes results in nerve damage and poor circulation to the legs and feet.

28 Sep 2009

Physicians should implement new measures while diagnosing prenatal Down syndrome

New prenatal tests for Down syndrome are soon to be offered to all pregnant women across the United States, yet telling an expectant couple that their child will be born with Down syndrome is a task very few physicians are trained for, claims research published in the American Journal of Medical Genetics.

28 Sep 2009

Universal bilirubin screening can reduce jaundice incidence in newborns

Screening all newborns for excessive bilirubin in the blood can significantly decrease the incidence of severe jaundice which, in extreme cases, can lead to seizures and brain damage, according to researchers at UCSF Children's Hospital and Kaiser Permanente's Division of Research in Oakland, CA.

28 Sep 2009

$Diabetic patients face increased risk of bone fractures$

Diabetic patients face increased risk of bone fractures

Current research suggests that the inflammatory molecule TNF-α may contribute to delayed bone fracture healing in diabetics. The related report by Alblowi et al, "High Levels of TNF-α Contribute to Accelerated Loss of Cartilage in Diabetic Fracture Healing" appears in the October 2009 issue of the American Journal of Pathology.

28 Sep 2009

Research reveals prophylactic mastectomy is on the rise

A new study of New York State data finds that the number of women opting for surgery to remove the healthy breast after a cancer diagnosis in one breast is rising, despite a lack of evidence that the surgery can improve survival.

28 Sep 2009

Rosiglitazone slows progression of cachexia in cancer affected mice

Insulin resistance, the hallmark of type 2 diabetes and a condition often associated with obesity, is paradoxically also an apparent contributor to muscle wasting and severe fat loss that accompanies some cancers, according to new research.

27 Sep 2009

Pfizer to commence Phase 3 trial of oral c-Met and ALK inhibitor

Pfizer Oncology announced today that it will initiate a global, Phase 3 clinical trial of its investigational oral c-Met and ALK inhibitor, PF-02341066, versus standard of care chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) carrying the ALK (anaplastic lymphoma kinases) fusion gene, who have progressed on one prior treatment with a platinum-based chemotherapy.

26 Sep 2009

European CHMP recommends Merck's JANUVIA and JANUMET as add-on to insulin

Merck & Co., Inc., which operates in many countries as Merck Sharp & Dohme (MSD), has received a positive opinion from the European Medicines Agency’s (EMEA) Committee for Medicinal Products for Human Use (CHMP) for JANUVIA® tablets and JANUMET® tablets recommending their use as add-on to insulin for the treatment of type 2 diabetes.

26 Sep 2009

European CHMP recommends marketing approval for Sanofi-aventis' Multaq

Sanofi-aventis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has adopted a positive opinion recommending to grant a marketing authorization in the European Union for Multaq(R) (dronedarone - 400mg Tablets).

26 Sep 2009

Personal approach to psychological well-being

At the World Congress on Psychosomatic Medicine in Torino, Italy, Carol Ryff, Professor of Psychology at the University of Wisconsin, has described how, more than simply feeling happy, it is the personal approach to psychological well-being that matters.

26 Sep 2009

G-bor Bal-zsi's innovative research in drug resistance earns select honor

A unique approach to understanding how cells develop resistance to drugs has won a scientist at The University of Texas M. D. Anderson Cancer Center a New Innovator Award from the National Institutes of Health.

26 Sep 2009